| Generated by Google Flow text-to-video AI software, powered by Veo 3 |
People ask me why I’m doing it. Why would I invest hundreds of millions of
dollars into developing a panacea when “there’s more money to be made in the
treatment”? To be clear, that’s actually a low number for developing even a
single drug, and that’s because we were coming at it with a huge advantage of
having a source for the cure, instead of having to start from scratch. So that
was one reason why we calculated that it was worth it. Number one after that
is that my name will go down into the history books as the woman who provided
the world with the greatest accomplishment humanity has ever achieved. Of
course, Landis will be at the top of the list, but no one’s going to remember
his nurse, or one of his patients. He cured millions. I’ll cure billions. And
I’ll keep doing it over and over again. We’re not sure if this drug will grant
virtual immortality, but honestly, I don’t see why not. And if it doesn’t,
we’ll work on that too. And we’ll be able to do that, because at that point,
we’ll be the only pharmaceutical company left in existence. The other ones,
who only ever hoped to sell treatments, will become obsolete, almost literally
overnight. Unless they diversified into selling diagnostic equipment—or, I
don’t know, something unrelated, like microwaves—they’re destined to have a
bad time. Their stock prices are already tanking in anticipation for an
announcement that we’ve made a breakthrough. People are actually saving money
that they would usually spend on medicine, because they think we’re preparing
to send them a fix tomorrow. Well, I can’t condone such behavior. Time is a
huge factor here. They’re close—my researchers are close—and I have been
funneling a lot of the money dedicated to this endeavor into bolstering mass
production, but we’re not there yet. My competitors want to get in on this,
and we will agree to that, because it will help with rollout, but I have
demands, and it all has to do with what I said; keeping my name at the top. I
curated the relationship with the Foundation. I made Mr. Tipton promises. I’m
in charge here, and if that slows down production, then so be it. People will
wait for months, because some have been waiting their whole lives, and
humanity has been waiting for thousands of years—at the risk of being too
specific. Pharmaceutical companies are known for being greedy and uncaring,
and I’m not going to sit here and try to tell you that it isn’t true. We
charge too much for insulin. We make our customers jump through hoops. We
didn’t make the industry the way it is today (not alone, anyway) but I admit
some fault. So in the end, that’s why I’m doing this. My competitors’
reputations are set. Nothing can be done to show them in a better light,
except maybe if they get in line, and help with production in the right way.
But no one will remember what we used to be. Once the panacea comes out, with
our label on every single inhaler, that’s what we’ll be known for. And the
world will be grateful. For us.
